Peptide Receptor Radionuclide Therapy (Lu-177 DOTATATE) in Progressive Neuroendocrine Tumors (NETs): Potential Predictors of Progression Free Survival (PFS)

被引：0
|
作者：
Badawy, Mohmed [1 ]
Johnson, Geoffrey B. [1 ]
Hobday, Timothy [1 ]
Packard, Annie T. [1 ]
Jain, Manoj [2 ]
Halfdanarson, Thorvardur R. [1 ]
Young, Jason R. [1 ]
Thorpe, Matthew P. [1 ]
Eiring, Rachel A. [1 ]
Kendi, Ayse Tuba [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
来源：
PANCREAS | 2022年 / 51卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
C-24
引用
收藏
页码：E42 / E42
页数：1
相关论文
共 50 条
  • [41] Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma
    Deville, Agathe
    Pinigina, Iuliia
    Al Mansour, Laure
    Abeillon, Juliette
    Tordo, Jeremie
    [J]. CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : E71 - E73
  • [42] Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action
    Assadi, Majid
    Rekabpour, Seyed Javad
    Amini, Abdullatif
    Dadgar, Habibollah
    Nemati, Reza
    Gholamrezanezhad, Ali
    Nabipour, Iraj
    Jafari, Esmail
    Ahmadzadehfar, Hojjat
    [J]. MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, 2021, 30 (02) : 107 - 109
  • [43] In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
    Lubberink, Mark
    Wilking, Helena
    Ost, Amalia
    Ilan, Ezgi
    Sandstrom, Mattias
    Andersson, Camilla
    Fross-Baron, Katarzyna
    Velikyan, Irina
    Sundin, Anders
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (09): : 1337 - 1340
  • [44] Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review
    Nautiyal, Amit
    Michopoulou, Sofia
    Guy, Matt
    [J]. CLINICAL AND TRANSLATIONAL IMAGING, 2024, 12 (02) : 157 - 175
  • [45] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
    Mok, S.
    Tay, Y.
    Ng, D.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [46] 177Lu DOTATATE nanoparticles: A therapeutic option for peptide receptor radionuclide therapy
    Arora, Geetanjali
    Shukla, Jaya
    Ghosh, Sourabh
    Malhotra, Arun
    Bandohpadhyaya, Guru
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [47] Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review
    Amit Nautiyal
    Sofia Michopoulou
    Matt Guy
    [J]. Clinical and Translational Imaging, 2024, 12 : 157 - 175
  • [48] Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    Alsadik, Shahad
    Gnanasegaran, Gopinath
    Chen, Luohai
    Mandair, Dalvinder
    Toumpanakis, Christos
    Caplin, Martyn
    Navalkissoor, Shaunak
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (10): : 1503 - 1508
  • [49] Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy
    Makis, William
    McCann, Karey
    Riauka, Terence A.
    McEwan, Alexander J. B.
    [J]. CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) : 877 - 879
  • [50] Dose response of pancreatic neuroendocrine tumours treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE
    Ilan, E.
    Sandstrom, M.
    Garske-Roman, U.
    Sundin, A.
    Wassberg, C.
    Lubberink, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S223 - S224
12345